# Phase 1/2 hematologic cancer trials recruiting: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 1/2 for hematologic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 hematologic cancer trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/hematologic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 14, 2026 | NCT07873827 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | Stemline Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | Hematological Malignancy | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873827) |
| July 24, 2026 | NCT07724873 | Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients | Tata Memorial Centre | Phase 1/2 | Recruiting | Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724873) |
| July 1, 2026 | NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of... | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Not yet recruiting | T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma, Relapsed/Refractory Hematologic Malignancies | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678307) |
| June 23, 2026 | NCT07662369 | CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation | Ruijin Hospital | Phase 1/2 | Recruiting | Hematologic Malignancy, Haplo-identical HCT | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662369) |
| June 5, 2026 | NCT07629726 | A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms | Kyowa Kirin Co., Ltd. | Phase 1/2 | Recruiting | Hematologic Neoplasms | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629726) |
| May 6, 2026 | NCT07570563 | Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Hematologic Malignancy, Solid Tumor | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570563) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| October 24, 2025 | NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | Daiichi Sankyo | Phase 1/2 | Recruiting | Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220616) |
| August 29, 2025 | NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07148180) |
| August 6, 2025 | NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | Biotroy Therapeutics | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM) | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07107204) |
| April 29, 2025 | NCT06948981 | GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies | Grit Biotechnology | Phase 1/2 | Recruiting | Hematological Malignancy (Leukemia- Lymphoma) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948981) |
| December 6, 2024 | NCT06720324 | CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1/2 | Recruiting | Hematologic Malignancy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06720324) |
| November 20, 2024 | NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | BeOne Medicines | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06697184) |
| March 27, 2024 | NCT06333509 | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | CARsgen Therapeutics Co., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma, Primary Plasma Cell Leukemia | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06333509) |
| January 16, 2024 | NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | Shenzhen TargetRx Co., Ltd. | Phase 1/2 | Recruiting | Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206174) |
| December 22, 2023 | NCT06180499 | Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion | Assistance Publique - Hôpitaux de Paris | Phase 1/2 | Not yet recruiting | Hematological Malignancies, Regulatory T Cell Depletion, Relapse | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06180499) |
| November 7, 2023 | NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Indapta Therapeutics, INC. | Phase 1/2 | Recruiting | NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory... | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06119685) |
| October 4, 2023 | NCT06066203 | A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Non-hodgkin's Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06066203) |
| July 13, 2023 | NCT05943067 | CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT | University Hospital Tuebingen | Phase 1/2 | Recruiting | Hematologic Malignancy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05943067) |
| July 22, 2022 | NCT05470491 | Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | HIV, Hematologic Malignancies | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05470491) |
| June 29, 2022 | NCT05436418 | The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05436418) |
| April 14, 2022 | NCT05327023 | Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Hematologic Neoplasms | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05327023) |
| April 12, 2022 | NCT05322850 | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | University of Florida | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05322850) |
| November 8, 2021 | NCT05110742 | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Hematological Malignancy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05110742) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Indapta Therapeutics, INC. | 1 |
| Chinese PLA General Hospital | 1 |
| [Stemline Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/stemline-therapeutics-inc) | 1 |
| University Hospital Tuebingen | 1 |
| [Kyowa Kirin Co., Ltd.](https://specstream.ai/data/clinical-trials/company/kyowa-kirin-co-ltd) | 1 |
| Ruijin Hospital | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| Medsyn Biopharma, LLC | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Biotroy Therapeutics | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| CellCentric Ltd. | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| Sellas Life Sciences Group | 1 |
| Curis, Inc. | 1 |
| Fred Hutchinson Cancer Center | 1 |
| [Grit Biotechnology](https://specstream.ai/data/clinical-trials/company/grit-biotechnology) | 1 |
| Shenzhen TargetRx Co., Ltd. | 1 |
| CARsgen Therapeutics Co., Ltd. | 1 |
| University of Florida | 1 |
| Smart Immune SAS | 1 |
| Tata Memorial Centre | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 9 |
| France | 5 |
| Italy | 2 |
| Spain | 2 |
| United Kingdom | 2 |
| Germany | 1 |
| Japan | 1 |
| Sweden | 1 |
| Czechia | 1 |
| Israel | 1 |
| Poland | 1 |
| India | 1 |
| Australia | 1 |
| Brazil | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Fireplace services in the United States](https://specstream.ai/data/businesses/fireplace-services/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Hospitals in the United States](https://specstream.ai/data/businesses/hospitals/united-states)
- [Internet service providers in the United States](https://specstream.ai/data/businesses/internet-service-providers/united-states)
